Accendra Health, Inc. · NYSE:ACH
Accendra Health — Bank of America Leveraged Finance Conference 2025
5 slides from Accendra Health's conference presentation, Dec 2, 2025
Slide 1: Bank of America Leveraged Finance Conference
Bank of America Leveraged Finance Conference December 2, 2025 1 Confidential & Proprietary to Owens & Minor, Inc.
Slide 2: Safe Harbor
This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This presentation contains certain “forward-looking” statements made pursuant to the Safe Harbor p
Slide 3: Key Investment Highlights
Key Investment Highlights • The sale of P&HS segment positions the company as a pure-play in the attractive home- based care business with a singular focus – capital allocation, strategic priorities, and execution are no longer split • Retaining higher-margin Patient Direct business enables Company
Slide 4: Free Cash Flow
Free Cash Flow Recent Actual Results ($M) 3Q2025 YTD 3Q2025 Adjusted EBITDA from continuing operations (non-GAAP) 92 285 Net capital expenditures from continuing operations (non-GAAP) (27) (99) Interest expense, net (consolidated company) (37) (107) Free cash flow (non-GAAP) $ 28 $ 78 Future Expecta
Slide 5: Updates & Reminders on the P&HS Sale Process
Updates & Reminders on the P&HS Sale Process • Closing remains on track for 1Q2026 or possibly by end of year 2025; separation planning is well underway with strong and involved partnership from Platinum team on a daily basis • $280M of current maturities noted in our form 10-Q for 3Q2025 represents
Accendra Health — Bank of America Leveraged Finance Conference 2025 on 6ix